HR 1873 · 117th Congress 2021โ€“2023, ended

Advancing Education on Biosimilars Act of 2021

Latest action · Mar 16, 2021 Referred to the Subcommittee on Health.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMar 12, 2021
  2. Passed HouseNot reached
  3. Passed SenateNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Advancing Education on Biosimilars Act of 2021

This bill requires the Food and Drug Administration (FDA) to advance education and awareness among health care providers about biological products as appropriate, including by developing or improving continuing education programs that address the prescribing of biological products and biosimilars. (A biosimilar is a biological product that is highly similar to an FDA-approved reference biological product and has no clinically meaningful differences from that reference product.)

The FDA may also maintain and operate a website to provide educational materials about biological products.

Cosponsors 1

Members who signed on, in the order they did. All signed on Mar 12, 2021.

SeatCosponsorSigned on
D-CAScott H. PetersOriginalMar 12, 2021

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Mar 12, 2021
Health Subcommittee
Referred Mar 16, 2021

Actions 3

Everything that happened, newest first.

  1. Mar 16, 2021Referred to the Subcommittee on Health.
  2. Mar 12, 2021Introduced in House
  3. Mar 12, 2021Referred to the House Committee on Energy and Commerce.

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: Article 1, Section 8, Clause 3

The sponsor’s statement, as printed in the Congressional Record, vol. 167, no. 47, March 12, 2021, page H1364.

Related bills 2

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
HR 19Lower Costs, More Cures Act of 2021Related billOct 19, 2021
S 164Advancing Education on Biosimilars Act of 2021Identical billApr 23, 2021

Titles 2

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To educate health care providers and the public on biosimilar biological products, and for other purposes.
Short Title(s) as Introduced
Advancing Education on Biosimilars Act of 2021

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Mar 12, 2021Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.